All AbMole products are for research use only, cannot be used for human consumption.
CTPI-2 is an inhibitor of mitochondrial citrate carrier SLC25A1 with KD of 3.5 μM. CTPI-2 is a unique regulator of glycolysis that limits the metabolic plasticity of cancer stem cells (CSCs). CTPI-2 inhibits glycolysis, PPARγ, and its downstream target the glucose transporter GLUT4. CTPI-2 halts salient alterations of NASH reverting steatosis, preventing the evolution to steatohepatitis, reducing inflammatory macrophage infiltration in the liver and adipose tissue, and starkly mitigating obesity induced by a high-fat diet.
| Molecular Weight | 356.74 |
| Formula | C13H9ClN2O6S |
| CAS Number | 68003-38-3 |
| Form | Solid |
| Solubility (25°C) | DMSO 100 mg/mL |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
| Related Mitochondrial Related Products |
|---|
| VLX600
VLX600 is a novel inhibitor of iron-chelated oxidative phosphorylation (OXPHOS). VLX600 causes mitochondrial dysfunction and can show enhanced cytotoxicity in nutrient deficiency conditions. VLX600 showed selective cytotoxic activity against malignant cells and induced autophagy and had anticancer activity.*The compound is unstable in solutions, freshly prepared is recommended |
| FCCP
FCCP is a mitochondrial uncoupling agent and an oxidative phosphorylation (OXPHOS) inhibitor. FCCP is often used as an apoptosis inducer. FCCP induces activation of PINK1 leading to Parkin Ser65 phosphorylation. |
| Lixumistat
Lixumistat (IM156) is a novel biguanide mitochondrial protein complex 1 inhibitor of oxidative phosphorylation (OXPHOS) with anti-tumor activity. Lixumistat regulates OXPHOS to attenuate mitochondrial metabolic reprogramming and inhibit lung fibrosis. Lixumistat (IM156) is a metformin derivative, which increases AMPK phosphorylation. |
| KL1333
KL1333 is an orally available, small organic molecule that reacts with NAD(P)H:quinone oxidoreductase 1 (NQO1) as a substrate, resulting in increases in intracellular NAD+ levels via NADH oxidation. |
| Mito-TEMPO
Mito-TEMPO (MT) is a mitochondrial-targeted superoxide dismutase mimetic that protects the early stages of acetaminophen (APAP) hepatotoxicity by inhibiting the formation of peroxynitrite. Mito-TEMPO treatment inhibits APAP-induced EXPRESSION OF RIP3 kinase. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.
